As the global prevalence of diabetes continues to rise, the medical community remains vigilant in identifying contributing factors and implementing preventive measures to mitigate its impact. A recent study, published on January 13, 2024, in the Journal of the Formosan Medical Association, sheds new light on the risk of developing New Onset Diabetes Mellitus (NODM) amongst patients undergoing dialysis – a lifesaving treatment for those with End-Stage Renal Disease (ESRD). The study’s findings suggest that the type of dialysis modality significantly influences the likelihood of patients developing NODM, particularly among individuals with preexisting prediabetes.

Background on ESRD and Dialysis Treatments

Patients with ESRD have lost most of their kidney function, requiring dialysis to remove waste products and extra fluid from the blood. There are two primary dialysis modalities: hemodialysis (HD) and peritoneal dialysis (PD). Both methods serve to filter blood in the absence of adequate kidney function, but they do so in different ways. HD uses an external machine and filter, requiring patients to visit a clinic several times a week, while PD uses the lining of the abdomen to filter blood inside the body, allowing for more flexibility and typically home-based treatment.

Comparative Analysis of Dialysis Modalities

The groundbreaking study led by Chen Yung-Tai from the Institute of Clinical Medicine at National Yang Ming Chiao Tung University, Taipei, Taiwan, along with colleagues Lin Chih-Ching, Huang Po-Hsun, and Li Szu-Yuan, involved a retrospective cohort analysis of 1,426 non-diabetic ESRD patients who had been treated with either HD or PD at a single medical center over a span of 12 years. A highlight of this research is the thorough consideration of various confounding factors such as the patients’ pre-dialysis glycemic status, medication usage, nutritional status, and even accounting for the competing risk of death, ensuring a more accurate assessment of the impact of dialysis modality on the development of NODM.

Results of the Study

Out of the cohort, 331 patients (23%) were found to have developed NODM. Upon adjusting for these confounding factors, the findings revealed that patients treated with PD were at a significantly higher risk of developing NODM compared to those treated with HD, with an adjusted hazard ratio (HR) of 1.52 and a p-value of 0.001. Further sensitivity analysis, employing a propensity-matched cohort, corroborated these results.

Risk in Prediabetic Patients

One of the most striking revelations of the research was the differential impact of dialysis modality on patients with prediabetes. Prediabetic individuals on PD were found to have an almost threefold higher risk (adjusted HR of 2.93) of progressing to NODM compared to those on HD. This association was not observed in patients who were euglycemic before commencing dialysis.

Significance of the Findings

The implications of developing NODM for dialysis patients are profound. The study also found that newly diabetic ESRD patients had a 1.78 times increased risk of major cardiovascular events, underscoring the serious health consequences that can stem from the onset of diabetes.

Implications for Nephrologists and Patient Care

The findings of this study underscore the need for nephrologists to consider a patient’s glycemic status when selecting a dialysis modality. This is particularly important as the data suggests that PD may pose a higher risk for NODM, especially for those already at risk due to prediabetes.

Future Directions and Personalized Treatment Approaches

The research team stressed the importance of developing personalized treatment approaches in managing ESRD patients. They highlight that an individualized assessment and careful selection of the dialysis method may optimize patient outcomes, potentially reducing the likelihood of developing diabetes.

It is worth noting that the research has limitations; being a retrospective analysis at a single center may restrict the generalizability of the findings. Moreover, the study controls for many variables, but residual confounding cannot be fully excluded.

Conclusion and Recommendations

The comprehensive study published in the Journal of the Formosan Medical Association offers valuable insights into managing ESRD and dialysis treatment. The study’s DOI is 10.1016/j.jfma.2024.01.013, with the identification number S0929-6646(24)00032-9, for those wishing to delve deeper into the analysis. The importance of such research lies not only in its immediate clinical implications but also in paving the way for future studies that may broaden our understanding of diabetes onset in patients with renal disease and how we can more effectively tailor our treatment options.

This research can potentially cause ripples throughout the medical community, catering to a greater emphasis on the role of glycemic status in the treatment of ESRD and encouraging further investigation into how dialysis modalities can be best utilized to maximize patient health outcomes and minimize additional health risks.


Chen, Y. T., Lin, C. C., Huang, P. H., & Li, S. Y. (2024). Comparative analysis of hemodialysis and peritoneal dialysis on the risk of new onset diabetes mellitus. Journal of the Formosan Medical Association = Taiwan yi zhi, S0929-6646(24)00032-9. Advance online publication.


1. New Onset Diabetes Mellitus
2. Hemodialysis vs Peritoneal Dialysis
3. Diabetes Risk in Dialysis Patients
4. ESRD Treatment Options
5. Prediabetes and Dialysis Choice